- Zogenix Acquires Brabant Pharma Drug Lead For Dravet Syndrome🔍
- Zogenix Acquires Brabant Pharma in Up to $130M Deal🔍
- Zogenix acquires U.K.|based Brabant Pharma🔍
- Zogenix Acquires U.K.|Based Brabant Pharma🔍
- Zogenix Inc. has acquired Brabant Pharma🔍
- UCB to acquire Zogenix🔍
- zgnx|20201231🔍
- Dr. Stephen Farr Appointed As CEO Of Zogenix 🔍
Zogenix Acquires Brabant Pharma Drug Lead For Dravet Syndrome
Zogenix Acquires Brabant Pharma Drug Lead For Dravet Syndrome
Pharmaceutical company Zogenix announced that it has acquired U.K.-based Brabant Pharma along with global rights to Brabafen...
Zogenix Acquires Brabant Pharma in Up to $130M Deal
Zogenix, a pharmaceutical company focused on the treatment ... Dravet syndrome, a rare form of intractable epilepsy that begins in infancy.
Zogenix acquires U.K.-based Brabant Pharma | Drug Discovery News
Obtains global rights for treatment option in development for Dravet syndrome, a rare and catastrophic form of epilepsy that begins in infancy.
Zogenix Acquires U.K.-Based Brabant Pharma | Fierce Biotech
Brabafen has recently received orphan drug designation in Europe and the U.S. for the treatment of Dravet syndrome. Children with Dravet ...
Zogenix Inc. has acquired Brabant Pharma - Global M&A Partners
... treatment of Dravet Syndrome. Brabant Pharma. Zogenix Inc. USA Based - Pharmaceutical Company Zogenix Acquires UK Bases Brabant Pharma for up to $130m. logo.
... treatment of seizures associated with Dravet syndrome. The U.S. Food and Drug Administration (FDA) has accepted for filing the company's ...
In October 2014, we acquired Brabant Pharma Limited (Brabant) in a ... drug applications in Japan for Dravet syndrome and LGS. Shinyaku will be ...
... drug designation in Europe and the United States for the treatment of Dravet syndrome. ... As partial consideration for the acquisition of Brabant ...
Dr. Stephen Farr Appointed As CEO Of Zogenix (ZGNX) To Lead ...
... acquisition of Brabant Pharma. The transformational acquisition of Brabant in October 2014 included a late-stage orphan drug candidate ...
Zeus advises on USD130m deal for Brabant Pharma - Private Equity ...
Drug development firm Brabant Pharma has been sold to US-based pharmaceutical company Zogenix ... treatment to Dravet syndrome, Brabafen. The ... The purchase of ...
an acquisition of Brabant Pharma, a privately-held U.K. ... treatment of a disease or disorder in the Field other than Dravet Syndrome.
Brabant Pharma - Company Profile - Tracxn
Brabant Pharma - Therapeutics for CNS diseases such as Dravet Syndrome. Acquired by Zogenix ... Its lead drug Brabafen is low-dose ...
Zogenix receives US patent entitled “Method for treatment of Dravet ...
... acquisition of Brabant Pharma Limited, pursuant to a sale and purchase agreement with Brabant. Related Articles. Supernus novel once-daily topiramate product ...
Zogenix, Inc. - Annual Reports
... acquired Brabant Pharma Limited, or Brabant, a privately-held company ... ZX008 has received orphan drug designation in Europe and the United States for the ...
Zogenix acquires UK-based Brabant Pharma for up to $130 million
Zogenix acquires UK-based Brabant Pharma for up to $130 million. ... New Dravet syndrome drug candidate scores in Phase III. 4 December ...
Analysis of an ongoing long‐term open‐label safety extension study
... Zogenix, Inc., and from Brabant Pharma (Manchester, UK). We confirm ... drug use in the European population with Dravet syndrome.
Zogenix Announces Issuance of U.S. Patent for ZX008 in Dravet ...
... treatment for Dravet syndrome seizures, enhancing CNS disorder therapies ... Brabant Pharma Limited, pursuant to a sale and purchase agreement with Brabant.
GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study ...
... treatment of both Dravet syndrome and Lennox-Gastaut syndrome. Additionally, GW has ... Zogenix Acquires Brabant Pharma, Drug Lead For Dravet Syndrome.
Fenfluramine provides clinically meaningful reduction in frequency ...
... Pharma outside the submitted work. S.M.Z. discloses research support from Epilepsy Research UK, Dravet Syndrome UK, and Zogenix, and has served as ...
UCB to buy Zogenix for nearly $2B in 'first step' for M&A in 2022
... Dravet syndrome. The Belgian drugmaker will add another $2 per share ... Since the Food and Drug Administration approved Fintepla, Zogenix ...